Barclays lowered the firm’s price target on Kura Oncology to $30 from $47 and keeps an Overweight rating on the shares post the Q3 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KURA:
- Kura Oncology files automatic mixed securities shelf
- Kura Oncology reports Q3 EPS (50c), consensus (55c)
- Kura Oncology Reports Third Quarter 2023 Financial Results
- Oppenheimer biotechnology analyst to hold an analyst/industry conference call
- Kura Oncology, Mirati Therapeutics enter clinical collab, supply agreement